Skip to main content
SpringerLink
Log in

Pharmacotherapy of Type 2 Diabetes Mellitus: An Update on Drug–Drug Interactions

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

The incidence of type 2 diabetes mellitus is increasing rapidly, as are the associated co-morbidities. Consequently, it has become necessary for a diabetic patient to take multiple medications at the same time to delay progression of the disease. This can put patients at an increased risk of moderate to severe drug interactions, which may threaten patients’ life or may deteriorate the quality of their life. Hence, managing drug–drug interactions is the cornerstone of anti-diabetic therapy. Most of the clinically important drug–drug interactions of anti-diabetic agents are related to their metabolic pathways, but drugs that compete for renal excretion or impair renal status can also play an important role. In this review, we have examined the clinical implications and underlying mechanisms of drugs that are likely to alter the pharmacologic response of or cause adverse events with antidiabetic drugs, and we have outlined safe and efficacious treatment modalities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–21.

    PubMed  Google Scholar 

  2. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91.

    PubMed  CAS  Google Scholar 

  3. Caughey GE, Roughead EE, Vitry AI, McDermott RA, Shakib S, Gilbert AL. Comorbidity in the elderly with diabetes: identification of areas of potential treatment conflicts. Diabetes Res Clin Pract. 2010;87(3):385–93.

    PubMed  Google Scholar 

  4. Rowland M, Tozer T, editors. Clinical pharmacokinetics: concepts and applications. 3rd ed. Baltimore, MD.: Williams & Wilkins; 1995.

  5. Standards of medical care in diabetes: 2013. Diabetes Care. 2013;36 Suppl 1:S11–S66.

  6. Phielix E, Szendroedi J, Roden M. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends Pharmacol Sci. 2011;32(10):607–16.

    PubMed  CAS  Google Scholar 

  7. Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol. 1979;16(3):195–202.

    PubMed  CAS  Google Scholar 

  8. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81–98.

    PubMed  CAS  Google Scholar 

  9. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care. 1997;20(6):925–8.

    PubMed  CAS  Google Scholar 

  10. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care. 2008;31(11):2086–91.

    PubMed  CAS  PubMed Central  Google Scholar 

  11. Masharani U. Diabetes mellitus & hypoglycemia. In: Papadakis MA, McPhee SJ, editors. Current Medical Diagnosis and Treatment, Chap 27. 49th ed. New york: McGraw-Hill Medical; 2009.

  12. Lalau JD, Race JM. Lactic acidosis in metformin-treated patients: prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf. 1999;20(4):377–84.

    PubMed  CAS  Google Scholar 

  13. Tomkin GH. Malabsorption of vitamin B12 in diabetic patients treated with phenformin: a comparison with metformin. Br Med J. 1973;3(5882):673–5.

    PubMed  CAS  PubMed Central  Google Scholar 

  14. Bell DS. Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. Southern Med J. 2010;103(3):265–7.

    PubMed  Google Scholar 

  15. Bauman WA, Shaw S, Jayatilleke E, Spungen AM, Herbert V. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care. 2000;23(9):1227–31.

    PubMed  CAS  Google Scholar 

  16. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol. 1987;23(5):545–51.

    PubMed  CAS  PubMed Central  Google Scholar 

  17. Baxter K, editor. Stockley’s drug interactions. 9th ed. London: Pharmaceutical Press; 2010.

    Google Scholar 

  18. Dawson D, Conlon C. Case study: metformin-associated lactic acidosis: could orlistat be relevant? Diabetes Care. 2003;26(8):2471–2.

    PubMed  Google Scholar 

  19. BMS. Glucophage (metformin hydrochloride). Bristol-Myers Squibb Company. US prescribing information. 2009.

  20. Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan Rao C, Madhusudan Rao Y. Effect of cephalexin on the pharmacokinetics of metformin in healthy human volunteers. Drug Metabol Drug Interact. 2002;19(1):41–8.

    PubMed  CAS  Google Scholar 

  21. Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther. 2011;89(6):837–44.

    PubMed  CAS  Google Scholar 

  22. Marathe PH, Wen Y, Norton J, Greene DS, Barbhaiya RH, Wilding IR. Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol. 2000;50(4):325–32.

    PubMed  CAS  PubMed Central  Google Scholar 

  23. Dachman AH. New contraindication to intravascular iodinated contrast material. Radiology. 1995;197(2):545.

    PubMed  CAS  Google Scholar 

  24. McCartney MM, Gilbert FJ, Murchison LE, Pearson D, McHardy K, Murray AD. Metformin and contrast media: a dangerous combination? Clin Radiol. 1999;54(1):29–33.

    PubMed  CAS  Google Scholar 

  25. Harrower AD. Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf. 2000;22(4):313–20.

    PubMed  CAS  Google Scholar 

  26. Holstein A, Beil W. Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Expert Opin Drug Metab Toxicol. 2009;5(3):225–41.

    PubMed  CAS  Google Scholar 

  27. Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet. 2005;44(12):1209–25.

    PubMed  CAS  Google Scholar 

  28. Krishnaiah YSR, Satyanarayana S, Visweswaram D. Interaction between tolbutamide and ketoconazole in healthy subjects. Br J Clin Pharmacol. 1994;37:205–207

  29. Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther. 2001;69(4):194–200.

    PubMed  CAS  Google Scholar 

  30. Loupi E, Descotes J, Lery N, Evreux JC. [Drug interactions involving miconazole]. Therapie. 1982;37(4):437–441.

  31. Niemi M, Neuvonen PJ, Kivisto KT. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther. 2001;70(5):439–45.

    PubMed  CAS  Google Scholar 

  32. Kubacka RT, Antal EJ, Juhl RP, Welshman IR. Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects. Ann Pharmacother. 1996;30(1):20–6.

    PubMed  CAS  Google Scholar 

  33. Bussing R, Gende A. Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction. Diabetes Care. 2002;25(9):1659–61.

    PubMed  Google Scholar 

  34. Rave K, Flesch S, Kuhn-Velten WN, Hompesch BC, Heinemann L, Heise T. Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp study. Diabetes Metab Res Rev. 2005;21(5):459–64.

    PubMed  CAS  Google Scholar 

  35. Barnett AH, Gonzalez-Auvert C, Pyke DA, Saunders JB, Williams R, Dickenson CJ, et al. Blood concentrations of acetaldehyde during chlorpropamide-alcohol flush. Br Med J (Clin Res Ed). 1981;283(6297):939–41.

    CAS  Google Scholar 

  36. Kelesidis T, Canseco E. Levofloxacin-induced hypoglycemia: a rare but life-threatening side effect of a widely used antibiotic. Am J Med. 2009;122(3):e3–4.

    PubMed  Google Scholar 

  37. Kelesidis T, Canseco E. Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect. Am J Med. 2010;123(2):e5–6.

    PubMed  Google Scholar 

  38. Feely J, Collins WC, Cullen M, el Debani AH, MacWalter RS, Peden NR, et al. Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H2-receptor antagonists. Br J Clin Pharmacol. 1993;35(3):321–3.

    PubMed  CAS  PubMed Central  Google Scholar 

  39. Kivisto KT, Neuvonen PJ. Enhancement of absorption and effect of glipizide by magnesium hydroxide. Clin Pharmacol Ther. 1991;49(1):39–43.

    PubMed  CAS  Google Scholar 

  40. Mahfouz M, Abdel-Maguid R, Dakhakhny M. Potentiation of the hypoglycaemic action of tolbutamide by different drugs. Arzneimittelforschung. 1970;20:120–122.

  41. Field JB, Ohta M, Boyle C, Remer A. Potentiation of acetohexamide hypoglycemia by phenylbutazone. N Engl J Med. 1967;277(17):889–94.

    PubMed  CAS  Google Scholar 

  42. Waller DG, Waller D. Hypoglycemia due to azapropazone-tolbutamide interaction. Br J Rheumatol. 1984;23:24–25.

  43. Goldshield. Rheumox (azapropazone dihydrate). Goldshield Pharmaceuticals, Ltd. Summary of products characteristics. 2000.

  44. Wing HMO. Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition. Br J Clin Pharmacol. 1985;20:482–5.

    PubMed  CAS  PubMed Central  Google Scholar 

  45. Tucker HS Jr. Hirsch JI. Sulfonamide-sulfonylurea interaction. N Engl J Med. 1972;286(2):110–1.

    Google Scholar 

  46. Christensen LK, Skovsted L. Inhibition of drug metabolism by chloramphenicol. Lancet. 1969;2(7635):1397–9.

    PubMed  CAS  Google Scholar 

  47. McKillop GFM, Slater SD. Possible interaction between heparin and a sulphonylurea a cause of prolonged hypoglycaemia? BMJ. 1986;296:1073.

    Google Scholar 

  48. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9(5):733–45.

    PubMed  CAS  Google Scholar 

  49. Kendall DMRM, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083–91.

    PubMed  CAS  Google Scholar 

  50. Zheng HX, Huang Y, Frassetto LA, Benet LZ. Elucidating rifampin’s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther. 2009;85(1):78–85.

    PubMed  CAS  PubMed Central  Google Scholar 

  51. Kivisto KT, Neuvonen PJ. The effect of cholestyramine and activated charcoal on glipizide absorption. Br J Clin Pharmacol. 1990;30(5):733–6.

    PubMed  CAS  PubMed Central  Google Scholar 

  52. Genzyme. Cholestagel (cholesevelam hydrochloride). Genzyme Therapeutics. UK summary of product characteristics. 2009.

  53. Zaman R, Kendall MJ, Biggs PI. The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide. Br J Clin Pharmacol. 1982;13(4):507–12.

    PubMed  CAS  PubMed Central  Google Scholar 

  54. FDA. U.S. Food and Drug Administration, Division of Dockets Management. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021290s012lbl.pdf. 2009. Accessed 25 July 2013.

  55. Zanchi A, Chiolero A, Maillard M, Nussberger J, Brunner HR, Burnier M. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab. 2004;89(3):1140–5.

    PubMed  CAS  Google Scholar 

  56. Hanefeld M. Pharmacokinetics and clinical efficacy of pioglitazone. Int J Clin Pract Suppl. 2001;121:19–25.

    PubMed  CAS  Google Scholar 

  57. Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos. 2000;28(7):772–80.

    PubMed  CAS  Google Scholar 

  58. Park JY, Kim KA, Shin JG, Lee KY. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. Br J Clin Pharmacol. 2004;58(4):397–402.

    PubMed  CAS  PubMed Central  Google Scholar 

  59. Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005;77(5):404–14.

    PubMed  CAS  Google Scholar 

  60. Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia. 2003;46(10):1319–23.

    PubMed  CAS  Google Scholar 

  61. Jaakkola T, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol. 2006;61(1):70–8.

    PubMed  CAS  PubMed Central  Google Scholar 

  62. Park JY, Kim KA, Kang MH, Kim SL, Shin JG. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther. 2004;75(3):157–62.

    PubMed  CAS  Google Scholar 

  63. Pedersen RS, Damkier P, Brosen K. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. Br J Clin Pharmacol. 2006;62(6):682–9.

    PubMed  CAS  PubMed Central  Google Scholar 

  64. Tornio A, Niemi M, Neuvonen PJ, Backman JT. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos. 2008;36(1):73–80.

    PubMed  CAS  Google Scholar 

  65. Hruska MW, Amico JA, Langaee TY, Ferrell RE, Fitzgerald SM, Frye RF. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. Br J Clin Pharmacol. 2005;59(1):70–9.

    PubMed  CAS  PubMed Central  Google Scholar 

  66. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24(7):1226–32.

    PubMed  CAS  Google Scholar 

  67. GSK. Avandia (rosiglitazone meleate). GlaxoSmithKline. US prescribing information. 2009.

  68. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–705.

    PubMed  CAS  Google Scholar 

  69. Idris I, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes Obes Metab. 2007;9(2):153–65.

    PubMed  CAS  Google Scholar 

  70. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010;12(8):648–58.

    PubMed  CAS  Google Scholar 

  71. Herman GA, Bergman A, Yi B, Kipnes M. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin. 2006;22(10):1939–47.

    PubMed  CAS  Google Scholar 

  72. Mistry GC, Bergman AJ, Zheng W, Hreniuk D, Zinny MA, Gottesdiener KM, et al. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol. 2008;66(1):36–42.

    PubMed  CAS  PubMed Central  Google Scholar 

  73. Mistry GC, Bergman AJ, Luo WL, Cilissen C, Haazen W, Davies MJ, et al. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol. 2007;47(2):159–64.

    PubMed  CAS  Google Scholar 

  74. LaSalle JR. Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs. Postgrad Med. 2010;122(1):144–52.

    PubMed  Google Scholar 

  75. Karim A, Laurent A, Munsaka M, Wann E, Fleck P, Mekki Q. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol. 2009;49(10):1210–9.

    PubMed  CAS  Google Scholar 

  76. Tiwari A. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Curr Opin Investig Drugs. 2009;10(10):1091–104.

    PubMed  CAS  Google Scholar 

  77. Bergman AJ, Cote J, Maes A, Zhao JJ, Roadcap BA, Sun L, et al. Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol. 2009;49(4):483–8.

    PubMed  CAS  Google Scholar 

  78. Wright DH, Herman GA, Maes A, Liu Q, Johnson-Levonas AO, Wagner JA. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 2009;49(10):1157–67.

    PubMed  CAS  Google Scholar 

  79. Miller JLME, Talaty JE, et al. The effect of MK-0431 on the pharmacokinetics of digoxin after concomitant administration for 10 days in healthy subjects [abstract no. PI-65]. Clin Pharmacol Ther. 2006;79(2):24.

    Google Scholar 

  80. He YL, Sabo R, Riviere GJ, Sunkara G, Leon S, Ligueros-Saylan M, et al. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin. 2007;23(5):1131–8.

    PubMed  CAS  Google Scholar 

  81. He YL, Sabo R, Sunkara G, Bizot MN, Riviere GJ, Leon S, et al. Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers [abstract]. J Clin Pharmacol. 2007;47(8):998–1004.

    PubMed  CAS  Google Scholar 

  82. Graefe-Mody U, Huettner S, Stahle H, Ring A, Dugi KA. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. Int J Clin Pharmacol Ther. 2010;48(6):367–74.

    PubMed  CAS  Google Scholar 

  83. He YL, Ligueros-Saylan M, Sunkara G, Sabo R, Zhao C, Wang Y, et al. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol. 2008;48(1):85–95.

    PubMed  CAS  Google Scholar 

  84. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009;54(3):516–23.

    PubMed  CAS  PubMed Central  Google Scholar 

  85. Patel CG, Li L, Girgis S, Kornhauser DM, Frevert EU, Boulton DW. Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. Clin Pharmacol. 2011;3:13–25.

    PubMed  CAS  PubMed Central  Google Scholar 

  86. Upreti VV, Boulton DW, Li L, Ching A, Su H, Lacreta FP, et al. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. Br J Clin Pharmacol. 2011;72(1):92–102.

    PubMed  CAS  PubMed Central  Google Scholar 

  87. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117(2):77–88.

    PubMed  CAS  Google Scholar 

  88. Vilsboll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs. 2007;16(2):231–7.

    PubMed  CAS  Google Scholar 

  89. Simonsen L, Holst JJ, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia. 2006;49(4):706–12.

    PubMed  CAS  Google Scholar 

  90. Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010;38(11):1944–53.

    PubMed  CAS  Google Scholar 

  91. Zinman B, Hoogwerf BJ, Duran Garcia S, Milton DR, Giaconia JM, Kim DD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146(7):477–85.

    PubMed  Google Scholar 

  92. Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268–78.

    PubMed  CAS  PubMed Central  Google Scholar 

  93. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32(7):1224–30.

    PubMed  CAS  PubMed Central  Google Scholar 

  94. Kothare PA, Linnebjerg H, Skrivanek Z, Reddy S, Mace K, Pena A, et al. Exenatide effects on statin pharmacokinetics and lipid response. Int J Clin Pharmacol Ther. 2007;45(2):114–20.

    PubMed  CAS  Google Scholar 

  95. Soon D, Kothare PA, Linnebjerg H, Park S, Yuen E, Mace KF, et al. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol. 2006;46(10):1179–87.

    PubMed  CAS  Google Scholar 

  96. Kothare PA, Soon DK, Linnebjerg H, Park S, Chan C, Yeo A, et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol. 2005;45(9):1032–7.

    PubMed  CAS  Google Scholar 

  97. Blase E, Taylor K, Gao HY, Wintle M, Fineman M. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects [abstract]. J Clin Pharmacol. 2005;45(5):570–7.

    PubMed  CAS  Google Scholar 

  98. Kapitza C, Zdravkovic M, Hindsberger C, Flint A. The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. Adv Ther. 2011;28(8):650–60.

    PubMed  CAS  Google Scholar 

  99. Malm-Erjefalt M, Ekblom M, Brondsed L, Vouis J, et al. A randomised, double-blind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects. In: Abstract book of the American Diabetes Association (ADA). 68th Scientific Sessions, San Francisco, CA; 6–10 June 2008.

  100. Brown GK. Glucose transporters: structure, function and consequences of deficiency. J Inherit Metab Dis. 2000;23(3):237–46.

    PubMed  CAS  Google Scholar 

  101. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217–24.

    PubMed  PubMed Central  Google Scholar 

  102. eMC. The electronic medicines compendium. EU summary of product characteristics. 2012. http://www.medicines.org.uk/emc/medicine/27188/SPC/Forxiga+5mg+%26+10+mg+film+coated+tablets. Accessed 20 July 2013.

  103. Janssen. Janssen Pharmaceuticals Inc. InvokanaTM (canagliflozin) tablets, for oral use: US prescribing information. 2013. http://www.janssenmd.com/pdf/invokana/PI-INVOKANA.pdf. Accessed 20 July 2013

  104. Kasichayanula S, Liu X, Shyu WC, Zhang W, Pfister M, Griffen SC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011;13(1):47–54.

    PubMed  CAS  Google Scholar 

  105. Janssen. Janssen Research & Development LLC. Advisory committee briefing materials: canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other anti-hyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus. Endocrinologic and Metabolic Drugs Advisory Committee. 2012:1–184.

  106. Kasichayanula S, Chang M, Liu X, Shyu WC, Griffen SC, LaCreta FP, et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012;29(2):163–77.

    PubMed  CAS  Google Scholar 

  107. Kasichayanula S, Liu X, Griffen SC, Lacreta FP, Boulton DW. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diabetes Obes Metab. 2013;15(3):280–3.

    PubMed  CAS  Google Scholar 

  108. Devineni D MP, Vaccaro N. Lack of clinically meaningful interaction between canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, and digoxin or warfarin in healthy subjects [abstract]. Clin Pharmacol Drug Dev. 2012;1:81.

  109. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899–906.

    PubMed  CAS  Google Scholar 

  110. Landon J, Wynn V, Samols E. The effect of anabolic steroids on blood sugar and plasma insulin levels in man. Metabolism. 1963;12:924–35.

    PubMed  CAS  Google Scholar 

  111. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2002;25(6):1033–41.

    PubMed  CAS  Google Scholar 

  112. Kolaczynski JW, Ylikahri R, Harkonen M, Koivisto VA. The acute effect of ethanol on counterregulatory response and recovery from insulin-induced hypoglycemia. J Clin Endocrinol Metab. 1988;67(2):384–8.

    PubMed  CAS  Google Scholar 

  113. Hedenmalm K, Hagg S, Stahl M, Mortimer O, Spigset O. Glucose intolerance with atypical antipsychotics. Drug Saf. 2002;25(15):1107–16.

    PubMed  CAS  Google Scholar 

  114. Korenyi C, Lowenstein B. Chlorpromazine induced diabetes. Dis Nerv Syst. 1968;29(12):827–8.

    PubMed  CAS  Google Scholar 

  115. Lipscombe LL, Levesque L, Gruneir A, Fischer HD, Juurlink DN, Gill SS, et al. Antipsychotic drugs and hyperglycemia in older patients with diabetes. Arch Intern Med. 2009;169(14):1282–9.

    PubMed  CAS  Google Scholar 

  116. Murphy MB, Lewis PJ, Kohner E, Schumer B, Dollery CT. Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up. Lancet. 1982;2(8311):1293–5.

    PubMed  CAS  Google Scholar 

  117. Henriksen JE, Alford F, Ward GM, Beck-Nielsen H. Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia. 1997;40(12):1439–48.

    PubMed  CAS  Google Scholar 

  118. Faul JL, Tormey W, Tormey V, Burke C. High dose inhaled corticosteroids and dose dependent loss of diabetic control. BMJ. 1998;317(7171):1491.

    PubMed  CAS  PubMed Central  Google Scholar 

  119. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154(1):97–101.

    PubMed  CAS  Google Scholar 

  120. Miccoli R, Orlandi MC, Fruzzetti F, Giampietro O, Melis G, Ricci C, et al. Metabolic effects of three new low-dose pills: a six-month experience. Contraception. 1989;39(6):643–52.

    PubMed  CAS  Google Scholar 

  121. Inglis AM, Miller AK, Culkin KT, Finnerty D, Patterson SD, Jorkasky DK, et al. Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. J Clin Pharmacol. 2001;41(6):683–90.

    PubMed  CAS  Google Scholar 

  122. Lilly E. Byetta (exenatide). UK summary of product characteristics: Eli Lilly and Company Ltd; 2009.

    Google Scholar 

  123. Spellacy WN. A review of carbohydrate metabolism and the oral contraceptives. Am J Obstet Gynecol. 1969;104(3):448–60.

    PubMed  CAS  Google Scholar 

  124. Garg AGS. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA. 1990;264(6):723–6.

    PubMed  CAS  Google Scholar 

  125. Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med. 1994;121(4):252–8.

    PubMed  CAS  Google Scholar 

  126. Prokai A, Fekete A, Pasti K, Rusai K, Banki NF, Reusz G, et al. The importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus. Pediatr Diabetes. 2012;13(1):81–91.

    PubMed  CAS  Google Scholar 

  127. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant Off J Am Soci Transplant Am Soc Transplant Surg. 2004;4(4):583–95.

    Google Scholar 

Download references

Disclosure Statement

No sources of funding were used to prepare this review. Muhammad Amin and Naeti Suksomboon have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand

    Muhammad Amin & Naeti Suksomboon

  2. Drug Regulatory Authority of Pakistan, Islamabad, Pakistan

    Muhammad Amin

Authors
  1. Muhammad Amin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naeti Suksomboon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Muhammad Amin.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Amin, M., Suksomboon, N. Pharmacotherapy of Type 2 Diabetes Mellitus: An Update on Drug–Drug Interactions. Drug Saf 37, 903–919 (2014). https://doi.org/10.1007/s40264-014-0223-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-014-0223-2

Keywords

Search

Navigation